MedTrace Logo

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

NCT02858804 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this study is to:

1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years);
2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.

Conditions

Interventions

DRUG

Etoposide

50 mg/m2, IV d1-4

DRUG

Doxorubicin

10 mg/m2, IV, d1-4

DRUG

Dexamethasone

30 mg/d, d1-5

DRUG

Vincristine

0.4 mg/m2, IV, d1-4

DRUG

Cyclophosphamide

750 mg/m2 ,d5

DRUG

Cytarabine

2g/m2, q12h, d1

DRUG

Cisplatin

100mg/ m2,IV, d1

DRUG

Rituximab

375 mg/m2 IV, d1

DRUG

Thalidomide

50-150mg/d, po, d1-28

DRUG

Prednisone

0.5mg/Kg, po, qod

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Shuhua Yi, Doc · Blood disease hospital, Chinese Academic Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-12-31
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02858804 on ClinicalTrials.gov